We have a strong track record in process optimization and robust process development of peptide molecules. Our team is highly experienced in handling all forms of peptide synthesis viz. solid, solution or hybrid phase peptides at our R and D centers in Hyderabad and Bangalore.
We have a dedicated peptide lab to support peptide synthesis, downstream purification, isolation and lyophilization.
As one of the leading CDMO, we have a state-of-the-art analytical laboratory for impurity characterization and profiling based on spectral methods.
We have one of the largest facilities to manufacture high-throughput synthesis of a wide variety of standard and complex peptides. We can manufacture various types of peptide classes with linear peptides up to 40 AA, conjugates of peptides such as small molecules, lipids, carbohydrates, and PEG. Cost effective LPPS approach for small peptides or linkers. We have expertise in process optimization and robust development for commercial manufacturing.
Our advanced technology with modern infrastructure enables us to produce up to 2 kg of linear and branched chain peptides. We provide peptide manufacturing services from our state-of- the-art manufacturing site in Vizag. The site is inspected by major regulatory bodies such as the US FDA, MHRA, and PMDA.
Class of Peptides We Handle
We can handle a wide range of peptides classes such as:
- Linear and branched chain peptides up to 40-mer AA (Natural and unnatural).
- Derivatives of peptides viz., small molecules/ carbohydrate/ PEG
- Peptides with multiple disulfide bridges, head-to-tail cyclization, and side-to-side cyclization
- Stappled, fluorescent and dyes.
- Cysteine rich peptides, lactam bridged peptides.
- Expertise in LPPS, SPPS and hybrid approaches
Lab Infrastructure to Support Peptide Development
Synthesizers
- Cost-effective LPPS approach for small peptides/linkers
- Manual reactors ranging from 100 mL to 10 L capacity (SPPS)
- CS Bio 936S: Automated peptide synthesizer fits for feasibility, optimization studies, pilot studies, and scale-up activities (1 to 5 L).
- CEM Automated Microwave Peptide Synthesizer-2 nos.
Lab -scale purification
- 3 preparative reverse phase HPLCs
- 1 MPLC flash system 250 mL/min pump capacity
- 1 Akta explorer ion exchange chromatography
- 1 Aktaprime plus ion exchange chromatography
- Gel permeation chromatography columns
Isolation techniques
- Crystallization
- Precipitation
- Lyophilization
- Virtis programmable tray of 3 L capacity
- Virtis benchtop of 1.5 L capacity
- Membrane filtration technology
- Tangential Flow Filtration (TFF) 1 kDa, 10kDa, and above
Analytical equipment to support peptide development
- LCMS, GC-MS, LC-Tof, LC Orbitrap, MALDI Tof instruments for characterization
- Multi-angle Light Scattering Detector (MALS)
- Circular Dichroism (CD) analysis for peptides
- 600 MHz nuclear magnetic resonance spectrometry
- Charged Aerosol Detector (CAD) for HPLC
- Amino acid analyzer with post-column derivatization
Clinical Supply Manufacturing
For your clinical supplies and commercial manufacturing needs, we provide peptide manufacturing services from our state-of-the-art manufacturing sites in Visakhapatnam. Both these sites are inspected by major regulatory bodies such as USFDA, MHRA, PMDA etc. Our facilities are equipped with microwave assist technology, liberty pro automatic synthesizers, and fully automated ion exchange purification systems.
Equipments for Peptide Synthesis
- Automated peptide synthesizer (80-160 L)
- Liberty pro peptide synthesizer (25 L)
- Microwave assisted peptide synthesizer
- Hastealloy ANFDs of 1m2 capacity for closed loop filtration operations
- Tangential flow filtration
- Separate peptide block (PB – 16) dedicated to peptides & polymers
Peptide Purification and Isolation
- Preparative RP-HPLC (150 to 600 mm diameter column, flow rate ranging from 3.3 to 20 LPH) with PAT blending technology.
- Fully automated ion exchange resin systems
- Freeze dryer – 100 L capacity (tray)
- Class 100K clean room area with Lyophilizers
Impurity Profiling and Characterization
- LCMS, GC-MS, LC-Tof, LC Orbitrap, MALDI Tof instruments for characterization
- Multi-angle Light Scattering (MALS) detector
- Circular Dichroism (CD) analysis for peptides
- 600 MHz nuclear magnetic resonance spectrometry
- Charged Aerosol Detector (CAD) for HPLC
- Amino acid analyzer with post-column derivatization
Why Aurigene Pharmaceutical services?
Extensive knowledge in developing & manufacturing hundreds of complex pharmaceutical products
Seamless integration from discovery to manufacturing
Capabilities across a wide range of peptide molecules
Large manufacturing capacities with automatic synthesizers
Rethink processes to ensure better quality in shorter timelines
Apply new science and technologies, to reduce costs or risk and add innovation
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Resources
APRIL 24, 2023
The importance of business continuity planning in CRDMO industry
Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...
Read More
Peptide Development and Manufacturing
Peptides are short chains of amino acids that are linked by peptide bonds. Several peptides linked together are called polypeptides. A protein contains one or more polypeptides. Therefore, proteins are long chains of amino acids held together by peptide bonds....
Read More
cGMP Development and Manufacturing Services
Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...
Read More
Expediting early development through innovative precision capsule filling technology
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...
Read More
Revisiting the reaction of b-chloroacroleins with 2-aminophenol: a new observation
2008
The reaction of b-chloroacrolein with 1 equiv of 2-aminophenol in DMF proceeds smoothly to afford 11-hydroxy derivative of chromenoquinoline in good yield. This single pot method allows for a rapid access to a variety of chromenoquinolines or oxepinoquinolines depending on the nature of b-chloroacrolein used. The structures were established by spectroscopic data ...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market